Second, while we carefully designed and performed the rescoring of all HER2-negative breast cancers to minimize potential bias resulting from interobserver differences and changes in diagnosis guidelines, the accurate discrimination of specific IHC scores is still challenging, especially in the low range (IHC 0 or 1+)49. This evidence concerns the gene ERBB2 and breast carcinoma.